title: Second International Conference on Cytokine Medicines.
abstract: The Second International Conference on Cytokine Medicine was held in Manchester, UK and was organised by an international consortium comprising leading clinicians and researchers from healthcare organisations, universities and industry, all with cognate interests in this field. The conference attracted a diverse mix of delegates including clinicians from a wide range of specialities, biomedical scientists, and a barrister with particular expertise in the legal aspects of care provision in healthcare systems. This meeting uniquely focused on cytokine therapies across the spectrum of medical problems, from bench to bedside, including emerging applications for cytokine therapies, issues raised by the delivery of cytokine medicines in clinical practice, and future developments in this broad and exciting area.
authors.affiliation: Division of Infection and Immunity, Clinical Sciences Centre, University Hospital Aintree, University of Liverpool, Longmoor Lane, Liverpool, L9 7AL, UK.
authors.forename: Theresa
authors.initials: T
authors.lastname: Barnes
authors.forename: John
authors.initials: J
authors.lastname: Goodacre
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Moots
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy / Q000378:metabolism; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004195:Disease Models, Animal; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000494:pharmacology; D000069285:Infliximab; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D002546:Ischemic Attack, Transient / Q000378:metabolism / Q000517:prevention & control; D011565:Psoriasis / Q000188:drug therapy; D018124:Receptors, Tumor Necrosis Factor; D012795:Sialoglycoproteins / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism; D014605:Uveitis / Q000188:drug therapy / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; C507763:IL1RN protein, human; D007074:Immunoglobulin G; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D018124:Receptors, Tumor Necrosis Factor; D012795:Sialoglycoproteins; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept; C472181:efalizumab